A selective cytopheretic inhibitory device to treat the immunological dysregulation of acute and chronic renal failure

Blood Purification

Volumn 29, Issue 2, 2010, Pages 183-190

  Humes, H David ^a,b   Sobota, Joseph T ^b   Ding, Feng ^c   Song, Joon Ho ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Nephrion Inc   (United States)

^c FUDAN UNIVERSITY   (China)

^d Inha University School of Medicine   (South Korea)

Author keywords

Cytopheretic inhibitory device; Immunological dysregulation; Renal failure, acute and chronic

Indexed keywords

CITRIC ACID; HEPARIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ARTIFICIAL KIDNEY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPHERETIC INHIBITORY DEVICE; FEMALE; HEMOFILTRATION; HOLLOW FIBER; HUMAN; IMMUNE DYSREGULATION; LEUKOCYTE ADHERENCE; LEUKOCYTE COUNT; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTIGEN-PRESENTING CELLS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CITRIC ACID; CYTOKINES; DOUBLE-BLIND METHOD; EQUIPMENT DESIGN; FEMALE; HEMOFILTRATION; HEPARIN; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES, PROXIMAL; LEUKOCYTE REDUCTION PROCEDURES; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 77749306473     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245645     Document Type: Article

References (50)

1. Stadnyk AW: Cytokine production by epithelial cells. FASEB J 1994; 8: 1041-1047.
2. Deneke SM, Fanburg BL: Regulation of cellular glutathione. Am J Physiol 1989; 257: L163-L173.
3. Tannen RL, Sastrasinh S: Response of ammonia metabolism to acute acidosis. Kidney Int 1984; 25: 1-10.
4. Maack T: Renal handling of proteins and polypeptides; in Windhager EE (ed): Handbook of Physiology. New York, Oxford University Press, 1992, pp 2039-2118.
5. Bishop GA, Waugh JA, Hall BM: Expression of HLA antigens on renal tubular cells in culture. II. Effect of increased HLA antigen expression on tubular cell stimulation of lymphocyte activation and on their vulnerability to cell-mediated lysis. Transplantation 1988; 46: 303-310.
6. Wahl P, Schoop R, Bilic G, Neuweiler J, Le Hir M, Yoshinaga SK, Wüthrich RP: Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol 2002; 13: 1517-1526.
7. Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, van Es LA: Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 1995; 48: 1477-1486.
8. Humes HD: Bioartificial kidney for full renal replacement therapy. Semin Nephrol 2000; 20: 71-82.
9. Kelly KJ: Acute renal failure: much more than a kidney disease. Semin Nephrol 2006; 26: 105-113.
10. Breen D, Bihari D: Acute renal failure as a part of multiple organ failure: the slippery slope of critical illness. Kidney Int Suppl 1998; 66:S25-S33.
11. Humes HD, MacKay SM, Funke AJ, Buffington DA: The bioartificial renal tubule assist device to enhance CRRT in acute renal failure. Am J Kidney Dis 1997; 30:S28-S31.
12. Okusa MD: The inflammatory cascade in acute ischemic renal failure. Nephron 2002; 90: 133-138.
13. Descamps-Latscha B: The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens 1993; 2: 883-891.
14. Descamps-Latscha B, et al: Immunological and chronic inflammatory abnormalities in end-stage renal disease; in Jacobs C, et al (eds): Replacement of Renal Function by Dialysis. Boston, Kluwer Academic, 1996.
15. Anding K, Gross P, Rost JM, Allgaier D, Jacobs E: The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant 2003; 18: 2067-2073.
16. Yoon JW, Pahl MV, Vaziri ND: Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 2007; 71: 167-172.
17. Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R, Kristal B: Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2431-2438.
18. Girndt M, Köhler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Büschenfelde KH, Fleischer B: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559-565.
19. Girndt M, Sester U, Kaul H, Köhler H: Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998; 9: 1689-1696.
20. Bloembergen WE, Stannard DC, Port FK, Wolfe RA, Pugh JA, Jones CA, Greer JW, Golper TA, Held PJ: Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 1996; 50: 557-565.
21. Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, Coyne DW, Gassman JJ, Kaufman AM, Kaysen GA, Lewis JA, Schwab SJ: Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003; 14: 1863-1870.
22. Sarnak MJ, Jaber BL: Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58: 1758-1764.
23. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
24. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
25. Girndt M, Sester U, Sester M, Kaul H, Köhler H: Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 1999; 14: 2807-2810.
26. Heine GH, Ulrich C, Seibert E, Seiler S, Marell J, Reichart B, Krause M, Schlitt A, Köhler H, Girndt M: CD14(++) CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008; 73: 622-629.
27. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M: IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233.
28. Descamps-Latscha B, Jungers P, Witko-Sarsat V: Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 2002; 20: 481-484.
29. Kaneider NC, Leger AJ, Kuliopulos A: Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. Febs J 2006; 273: 4416-4424.
30. Maroszynska I, Fiedor P: Leukocytes and endothelium interaction as rate limiting step in the inflammatory response and a key factor in the ischemia-reperfusion injury. Ann Transplant 2000; 5: 5-11.
31. Ding F, Song JH, Lou L, Rojas A, Reoma JL, Cook KE, Smith PL, Buffington DA, Humes HD: Novel selective cytopheretic inhibitory device (SCD) inhibits circulating leukocyte activation and ameliorates multiorgan dysfunction in a porcine model of septic shock. J Am Soc Nephrol 2008; 19: 458A.
32. Humes HD, Buffington DA: Selected cytopheresis device and related methods thereof. US patent WO2009/02981. June 4, 2009.
33. Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP, Luderer JR, Sobota J: Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004; 66: 1578-1588.
34. Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK, Szerlip HM, Ye J, Paganini EP, Dworkin L, Finkel KW, Kraus MA, Humes HD: Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008; 19: 1034-1040.
35. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL: Platelets and shear stress. Blood 1996; 88: 1525-1541.
36. Cubattoli L, Teruzzi M, Cormio M, Lampati L, Pesenti A: Citrate anticoagulation during CVVH in high risk bleeding patients. Int J Artif Organs 2007; 30: 244-252.
37. Nurmohamed SA, Vervloet MG, Girbes AR, Ter Wee PM, Groeneveld AB: Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study. Blood Purif 2007; 25: 316-323.
38. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265.
39. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T: Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care 2005; 20: 155-161.
40. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367.
41. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-552.
42. Waikar SS, Liu KD, Chertow GM: Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 2008; 3: 844-861.
43. Imai E, Iwatani H: The continuing story of renal repair with stem cells. J Am Soc Nephrol 2007; 18: 2423-2424.
44. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
45. Fissell WH, Dyke DB, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, Gutierrez JM, Humes HD: Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif 2002; 20: 55-60.
46. Fissell WH, Lou L, Abrishami S, Buffington DA, Humes HD: Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 2003; 14: 454-461.
47. Humes HD, Buffington DA, Lou L, Abrishami S, Wang M, Xia J, Fissell WH: Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med 2003; 31: 2421-2428.
48. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA: Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004; 65: 1357-1365.
49. Strippoli GF, Craig JC: Sunset for statins after AURORA? N Engl J Med 2009; 360: 1455-1457.
50. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.